Dose escalation with repeated intrathecal injections of 1311 labelled MAbs for the treatment of central nervous system malignancies
1998

Repeated Intrathecal Injections of Radioimmunoconjugates for CNS Tumors

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): JT Kemshead, K Hopkins, B Pizer, V Papanastassiou, H Coakham, J Bullimore, C Chandler

Primary Institution: University of Bristol

Hypothesis

Can repeated intrathecal injections of 131I-labelled monoclonal antibodies improve treatment outcomes for central nervous system malignancies?

Conclusion

The study suggests that repeated administration of 131I-MAb can increase the therapeutic index without causing significant toxicity.

Supporting Evidence

  • Patients received between 2026 and 2959 MBq of 131I-MAbs as their initial injection.
  • Up to 5920 MBq of 131I-MAb was administered without significant toxicity.
  • Pharmacokinetic studies showed that the clearance of the radioimmunoconjugate from the CSF remained constant.

Takeaway

Doctors gave medicine directly into the spine of kids with brain tumors to help them get better, and it worked without making them sick.

Methodology

Eight patients received repeated intrathecal injections of 131I-MAb, and pharmacokinetic data were collected to assess clearance from cerebrospinal fluid and blood.

Limitations

The small sample size limits the generalizability of the findings.

Participant Demographics

Five of the eight patients were children, with various diagnoses including primitive neuroectodermal tumors and carcinomatous meningitis.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication